Ponatinib (AP24534)

Name: Ponatinib (AP24534)
Brand: Selleck Chemicals
SKU: S1490
Rating: 5 (83 reviews)

For research use only. Not for use in humans.

Catalog No.S1490

83 publications

Molecular Weight(MW): 532.56

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Selleck's Ponatinib (AP24534) has been cited by 83 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )
Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )
Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )
Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NGnQ[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TRXmlEPTB;MD6wNFAxODByM{W5JO69VQ>?	NW\wRXVUW0GQR1XS
MV-4-11	M3v0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnyyTWM2OD1yLkCwNFA6PTZizszN	MmPBV2FPT0WU
MEG-01	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfu[\|A5UUN3ME2wMlAxODF{ODFOwG0>	Mmi0V2FPT0WU
LAMA-84	NGfjUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVqwRm5LUUN3ME2wMlAxODF4NTFOwG0>	MkfqV2FPT0WU
CGTH-W-1	NWixcJlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[yTWM2OD1yLkCwNVY6KM7:TR?=	NXnSWWZ7W0GQR1XS
KASUMI-1	NIC1WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi4cHVLUUN3ME2wMlAxOjF5IN88US=>	NV\abmh3W0GQR1XS
BE-13	Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1y5U2lEPTB;MD6wNFI2QSEQvF2=	Mn:3V2FPT0WU
CTV-1	M1P0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnT1TWM2OD1yLkCwOVIyKM7:TR?=	NUHIdXhiW0GQR1XS
NKM-1	M{\iWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrqTWM2OD1yLkCwOlU2KM7:TR?=	MV7TRW5ITVJ?
MONO-MAC-6	NGrSRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LNT2lEPTB;MD6wNFg{PyEQvF2=	MUfTRW5ITVJ?
A204	NGXYZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorDTWM2OD1yLkCxNlE5KM7:TR?=	NGrwdG5USU6JRWK=
GDM-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHhdI5KSzVyPUCuNFE5OzNizszN	M3nV[XNCVkeHUh?=
AN3-CA	NXnkbYxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXz2[lc6UUN3ME2wMlAyQDd\|IN88US=>	MmHWV2FPT0WU
BL-70	NGTYT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEKxPVkh\|ryP	NGLVTlJUSU6JRWK=
Daudi	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnHWpBKSzVyPUCuNFI2OzdizszN	NILUdZRUSU6JRWK=
KU812	M1rNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEK4OFgh\|ryP	MmHBV2FPT0WU
KG-1	NVrpR5ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnNNmZqUUN3ME2wMlA{Ojl2IN88US=>	MYrTRW5ITVJ?
DOHH-2	M1uzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;NTWM2OD1yLkC0PFA{KM7:TR?=	MWPTRW5ITVJ?
HuO9	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPXfmtUUUN3ME2wMlA2PDR6IN88US=>	NIf6dnFUSU6JRWK=
EB2	NFfFVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEW1O\|Yh\|ryP	M4DmWXNCVkeHUh?=
G-402	NWKwdYhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwME[zOFEh\|ryP	MV\TRW5ITVJ?
SU-DHL-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPaTWM2OD1yLkC2N\|c6KM7:TR?=	NGW1OpNUSU6JRWK=
NCI-H719	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S3SWlEPTB;MD6wO\|g5QCEQvF2=	NGHL[W1USU6JRWK=
MLMA	NYWzNGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjFZ497UUN3ME2wMlA6ODZizszN	NHvIdZFUSU6JRWK=
KM12	NV;a[W56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPPTWM2OD1yLkC5O\|M4KM7:TR?=	NInwc4NUSU6JRWK=
SUP-T1	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\RcmlEPTB;MD6wPVk5OiEQvF2=	NIfmZ5FUSU6JRWK=
MZ1-PC	NILVNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P6NGlEPTB;MD6xNVM{PiEQvF2=	MlLnV2FPT0WU
MFE-296	M{nEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO3UGdrUUN3ME2wMlEyQDN7IN88US=>	NGLze2dUSU6JRWK=
ALL-PO	NULiU\|NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHm[mdkUUN3ME2wMlEzPDR\|IN88US=>	MorqV2FPT0WU
GB-1	NHjCTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnRWYV2UUN3ME2wMlEzPTF{IN88US=>	MWnTRW5ITVJ?
SIG-M5	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfP[lRZUUN3ME2wMlE{OzdizszN	M{jJOHNCVkeHUh?=
P30-OHK	NVW1d\|lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMUW2O\|Ih\|ryP	M{jZdnNCVkeHUh?=
NCI-H716	NUPSR5pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnRWY9QUUN3ME2wMlE3OjZ4IN88US=>	M37vfnNCVkeHUh?=
MPP-89	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXaUHVKSzVyPUCuNVY6OzNizszN	MUDTRW5ITVJ?
SF126	M4\JdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrmeZpOUUN3ME2wMlE4ODZ\|IN88US=>	MYTTRW5ITVJ?
CTB-1	M3KyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3YTWM2OD1yLkG3N\|E3KM7:TR?=	NYXtTnQyW0GQR1XS
CA46	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLYXXpFUUN3ME2wMlE4PDh7IN88US=>	NX\RWJkyW0GQR1XS
NCI-H520	NYHYeIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMUe3N\|Ih\|ryP	M2fRTXNCVkeHUh?=
CAL-85-1	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMUe5Nlch\|ryP	MkXDV2FPT0WU
NCI-H2342	MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfsZ4hKSzVyPUCuNVg2PzdizszN	MWLTRW5ITVJ?
697	Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn3TWM2OD1yLkG4PFcyKM7:TR?=	NV7BWlRqW0GQR1XS
NY	M{nQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYr2SWFFUUN3ME2wMlE6Ojh5IN88US=>	NGPXNYZUSU6JRWK=
T98G	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q4bmlEPTB;MD6xPVMyQCEQvF2=	NIrGcZJUSU6JRWK=
NCI-H1703	NXnXdG5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PIcWlEPTB;MD6xPVYyPSEQvF2=	NWDtVGd1W0GQR1XS
NCI-H2087	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fuSmlEPTB;MD6yNFQ{QSEQvF2=	M3rxbXNCVkeHUh?=
PF-382	NGX5XINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDSOlEyUUN3ME2wMlIxQDd\|IN88US=>	MYHTRW5ITVJ?
HCT-116	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorvTWM2OD1yLkKxNFY6KM7:TR?=	NUP4eHFQW0GQR1XS
CAKI-1	NGX1R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jiS2lEPTB;MD6yNVY3PiEQvF2=	MYrTRW5ITVJ?
CCF-STTG1	NFvqfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXZc3NUUUN3ME2wMlIzPDd3IN88US=>	MknuV2FPT0WU
D-392MG	NYLuT2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHj3S\|ZKSzVyPUCuNlMyPzdizszN	MYfTRW5ITVJ?
RT-112	NVnURWRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXztTHVjUUN3ME2wMlI{Pzl3IN88US=>	MVXTRW5ITVJ?
MES-SA	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S2SGlEPTB;MD6yOFE5PyEQvF2=	MWTTRW5ITVJ?
LC-2-ad	M3LDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXZTWM2OD1yLkK0NlY2KM7:TR?=	MmLkV2FPT0WU
NOS-1	NIf4SJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMkSzOlch\|ryP	NVTYdG5sW0GQR1XS
NALM-6	NVLi[Fl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXYTWM2OD1yLkK1OVQ{KM7:TR?=	MWHTRW5ITVJ?
TE-15	NHrxeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGH3b3FKSzVyPUCuNlYxQTFizszN	MUDTRW5ITVJ?
786-0	NFXsenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\uXJRKSzVyPUCuNlYzOjhizszN	M4XvU3NCVkeHUh?=
IST-MES1	NWTRPGZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\STWM2OD1yLkK2PFI6KM7:TR?=	MmW1V2FPT0WU
KYSE-180	NU\HRnlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\mO2lEPTB;MD6yOlg6OSEQvF2=	M1\nZnNCVkeHUh?=
YT	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LlemlEPTB;MD6yOlk4PCEQvF2=	NYDybZlqW0GQR1XS
A427	NYHqXI5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLDT4tnUUN3ME2wMlI4OjZ2IN88US=>	MYfTRW5ITVJ?
KYSE-450	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXoWFk4UUN3ME2wMlI4OzJ7IN88US=>	NEPQSotUSU6JRWK=
HuH-7	NXPLSnJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjHTWM2OD1yLkK3O\|Y{KM7:TR?=	MWLTRW5ITVJ?
CAS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfWWWlvUUN3ME2wMlI5OzB\|IN88US=>	NW[0eINwW0GQR1XS
KURAMOCHI	M3S2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHrTWM2OD1yLkK4OFE6KM7:TR?=	NEL1WVdUSU6JRWK=
ACHN	NV7wbHR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HEbGlEPTB;MD6yPVMzOyEQvF2=	M4nndnNCVkeHUh?=
HGC-27	NWfodmZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVW3XXhXUUN3ME2wMlI6OzV\|IN88US=>	MljCV2FPT0WU
A172	M1\OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r0N2lEPTB;MD6yPVU4PyEQvF2=	M2f4THNCVkeHUh?=
SNU-449	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWH6fG55UUN3ME2wMlI6QTZ2IN88US=>	NIDaXJNUSU6JRWK=
SW982	M4i2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2X6W2lEPTB;MD6yPVk4QCEQvF2=	NE\yPWdUSU6JRWK=
EFO-21	NInOTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnCVGdKSzVyPUCuN\|A1OTFizszN	NHf4S3dUSU6JRWK=
NCI-H2030	NWjhNYdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzIfZJiUUN3ME2wMlMyOTZ2IN88US=>	M4jabnNCVkeHUh?=
HT-144	NG\a[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvvSm95UUN3ME2wMlMyOjhizszN	M2S5WnNCVkeHUh?=
MFE-280	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2K5NmlEPTB;MD6zNVQ2OyEQvF2=	M3;EdXNCVkeHUh?=
SK-LU-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\2eXpuUUN3ME2wMlMyPDZ4IN88US=>	M37leHNCVkeHUh?=
NCI-H2052	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\YS5dKSzVyPUCuN\|E1QDRizszN	NIPuTZlUSU6JRWK=
SK-HEP-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvyNoNyUUN3ME2wMlM{OzZ6IN88US=>	M3rSeHNCVkeHUh?=
QIMR-WIL	M2TxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwM{O0NlQh\|ryP	NF;RTWpUSU6JRWK=
A2780	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr4TWM2OD1yLkO0N\|A1KM7:TR?=	NWjkXZVxW0GQR1XS
ACN	M3\BeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkGyTWM2OD1yLkO0PFc{KM7:TR?=	NVflOm1IW0GQR1XS
BxPC-3	NHvPRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwM{S5PFkh\|ryP	MX\TRW5ITVJ?
BCPAP	NYK5S29XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7PTWM2OD1yLkO2NFAyKM7:TR?=	NV;mUmJ{W0GQR1XS
HOP-62	M4[4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLFTWM2OD1yLkO2NVA3KM7:TR?=	MXnTRW5ITVJ?
SW1710	NW[wWVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwM{[0OVUh\|ryP	MmL0V2FPT0WU
OPM-2	NV2zfVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwM{[0O\|Mh\|ryP	M3jjV3NCVkeHUh?=
DBTRG-05MG	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH0RlhvUUN3ME2wMlM5ODV2IN88US=>	NVi1XZNVW0GQR1XS
SK-MEL-24	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3z3emlEPTB;MD6zPVc6OSEQvF2=	MUnTRW5ITVJ?
8305C	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwM{m3PVMh\|ryP	MVTTRW5ITVJ?
OVCAR-4	NECwOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnRV2lKSzVyPUCuOFE2QDZizszN	NEHJ[oFUSU6JRWK=
HLE	NIjJVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXtdHRKSzVyPUCuOFE5PiEQvF2=	NF;Sc2hUSU6JRWK=
NCI-H747	NIeyfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TIcGlEPTB;MD60NlE{PyEQvF2=	M3fPdnNCVkeHUh?=
SW780	NYm5PXRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LpOGlEPTB;MD60NlM1PiEQvF2=	Mn3WV2FPT0WU
KYSE-150	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjhV5dKUUN3ME2wMlQzPDF3IN88US=>	MV3TRW5ITVJ?
H4	NYnK[IVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;ZVGM{UUN3ME2wMlQzPDVzIN88US=>	M2\HW3NCVkeHUh?=
SW1088	NF3ObJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLtblQzUUN3ME2wMlQ1OzlizszN	MnnwV2FPT0WU
SF268	NYP0dHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC0TWM2OD1yLkS0PFYh\|ryP	MW\TRW5ITVJ?
RT4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rMdGlEPTB;MD60OVEyOSEQvF2=	NXG3Tm0{W0GQR1XS
NCI-H522	NIDXbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwNEWyO{DPxE1?	NFjQXYVUSU6JRWK=
LCLC-97TM1	NHr6UI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LkVGlEPTB;MD60OlE6PSEQvF2=	NHX3clRUSU6JRWK=
CAL-39	MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\S[5lKSzVyPUCuOFY2OTlizszN	MofEV2FPT0WU
CAL-120	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfwT4VOUUN3ME2wMlQ4PjR\|IN88US=>	NX63SZhxW0GQR1XS
ESS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD5ZmlvUUN3ME2wMlQ4QDJzIN88US=>	MnXVV2FPT0WU
KARPAS-45	NXjQNGNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DrUWlEPTB;MD60PFk{OyEQvF2=	M2DEZXNCVkeHUh?=
DU-4475	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNEm1NVEh\|ryP	NVW4TGtMW0GQR1XS
VMRC-RCZ	NXnicYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwNEm5NFQh\|ryP	MY\TRW5ITVJ?
HOS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzLb4tYUUN3ME2wMlUxOzZ3IN88US=>	Mn;rV2FPT0WU
MOLT-16	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITTRYxKSzVyPUCuOVE5ODhizszN	MXXTRW5ITVJ?
RPMI-6666	NVzBd\|NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrjRpNsUUN3ME2wMlUzOTN3IN88US=>	M{fkRnNCVkeHUh?=
K052	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHiRoduUUN3ME2wMlUzOTRizszN	Mk\sV2FPT0WU
EHEB	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7IeWtSUUN3ME2wMlUzOTh{IN88US=>	MYLTRW5ITVJ?
MFH-ino	NVvDUJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljDTWM2OD1yLkWyN\|UyKM7:TR?=	MlfBV2FPT0WU
A4-Fuk	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV30XnVHUUN3ME2wMlUzPTJ6IN88US=>	MV7TRW5ITVJ?
SW1417	M4HQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTLO\|Z{UUN3ME2wMlUzPzhzIN88US=>	M1vBSnNCVkeHUh?=
DoTc2-4510	NFTPdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLLeJZKSzVyPUCuOVQ6PThizszN	Mk[2V2FPT0WU
TE-12	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;BPGlEPTB;MD61OVc{PSEQvF2=	M4rqZnNCVkeHUh?=
8-MG-BA	NFXPNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInVW3JKSzVyPUCuOVYxPTZizszN	M3ewWXNCVkeHUh?=
ECC12	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCwTYJKSzVyPUCuOVY2PThizszN	MnjMV2FPT0WU
CHL-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjpTWM2OD1yLkW3OFY{KM7:TR?=	M{LPbnNCVkeHUh?=
LCLC-103H	NID3VG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LZWGlEPTB;MD61PFM1PCEQvF2=	M3TYS3NCVkeHUh?=
OS-RC-2	M160[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwNUizO\|kh\|ryP	NG\2c29USU6JRWK=
RO82-W-1	NUH0b2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmOyTWM2OD1yLkW5OlE2KM7:TR?=	NH;mcVlUSU6JRWK=
A3-KAW	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;5UmlEPTB;MD62NVQ3PyEQvF2=	Mnr4V2FPT0WU
NCCIT	NXvpWoNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3WU3M6UUN3ME2wMlYyPzF3IN88US=>	NULqXJU3W0GQR1XS
IST-SL2	M4jnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwNkK1NlIh\|ryP	MorWV2FPT0WU
GI-ME-N	M2HvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwNkOwOlkh\|ryP	MXnTRW5ITVJ?
ES6	NV;Fem1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHrTWM2OD1yLk[zNlk2KM7:TR?=	M4HmNnNCVkeHUh?=
BL-41	NFvsNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\VVohCUUN3ME2wMlY{OzV{IN88US=>	NEHQWYNUSU6JRWK=
Ca-Ski	NIqxVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLpRYJKSzVyPUCuOlQ5OSEQvF2=	NGPSWYhUSU6JRWK=
HOP-92	M2nmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Pnd2lEPTB;MD62OVY4OiEQvF2=	M4DGUHNCVkeHUh?=
SK-LMS-1	M1rveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W5TmlEPTB;MD62OlQ4KM7:TR?=	NFn6V4VUSU6JRWK=
EW-13	NGD6ZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXqySGVJUUN3ME2wMlY3Pzd7IN88US=>	MnfKV2FPT0WU
647-V	M3XJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvnWFJKSzVyPUCuOlgyPDhizszN	M1LUbXNCVkeHUh?=
JiyoyeP-2003	NWX3TFQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LJfGlEPTB;MD62PVc{QCEQvF2=	NGi4fFJUSU6JRWK=
WSU-NHL	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[4TWM2OD1yLkewPFg4KM7:TR?=	NWjSTogzW0GQR1XS
U-698-M	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{D6WGlEPTB;MD63NVA3OyEQvF2=	MXnTRW5ITVJ?
HC-1	NHniNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnaeIRKSzVyPUCuO\|I1ODVizszN	NEW3WJBUSU6JRWK=
8505C	M3XzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPpTWM2OD1yLkeyO\|QyKM7:TR?=	NFXEbWhUSU6JRWK=
HUTU-80	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTYTWM2OD1yLkezN\|Q6KM7:TR?=	NX;JdlRYW0GQR1XS
LB1047-RCC	M1G3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7hdZRKSzVyPUCuO\|M2OzhizszN	Mo\WV2FPT0WU
GAMG	NInHSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlriTWM2OD1yLkezOlU{KM7:TR?=	NH\HOJdUSU6JRWK=
CAL-12T	NVn6fZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;oU2lEPTB;MD63N\|g4PyEQvF2=	NXvtSmpnW0GQR1XS
NCI-SNU-1	NEK1S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXKO3JKSzVyPUCuO\|czPzhizszN	NUDlS297W0GQR1XS
HTC-C3	M1fNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrBOZdKUUN3ME2wMlc4PDVzIN88US=>	M1X4SnNCVkeHUh?=
HPAF-II	MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjjTWM2OD1yLke3OVAyKM7:TR?=	MmnaV2FPT0WU
KGN	M3PlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwN{iwPFEh\|ryP	Mnf6V2FPT0WU
EFO-27	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwN{i3N\|Mh\|ryP	NVrhUolvW0GQR1XS
MEL-HO	NXPZc2FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\MZ\|RrUUN3ME2wMlc6PDR7IN88US=>	Mk[5V2FPT0WU
KYSE-270	M2XUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1qz[GlEPTB;MD64NFUzQSEQvF2=	MX3TRW5ITVJ?
NCI-H1755	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPFWlVKSzVyPUCuPFA4OTRizszN	MYPTRW5ITVJ?
MFM-223	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTaTWM2OD1yLkixOFA4KM7:TR?=	MlzlV2FPT0WU
G-361	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnMc\|FOUUN3ME2wMlgyQDl5IN88US=>	NGTjUI9USU6JRWK=
ETK-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nkRWlEPTB;MD64NlQ1OSEQvF2=	MWfTRW5ITVJ?
LU-99A	NWTSZlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3PTWM2OD1yLki0O\|AyKM7:TR?=	NUjCXpNqW0GQR1XS
IST-MEL1	MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwOEW3N\|Ih\|ryP	NGHtVmZUSU6JRWK=
L-540	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zPOGlEPTB;MD64OVgxOSEQvF2=	M3XIdXNCVkeHUh?=
U-2-OS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4W5[2lEPTB;MD64OVg1PiEQvF2=	NXLQXHZKW0GQR1XS
HT-1376	NIXKWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwOE[wOVEh\|ryP	NWPNWnJxW0GQR1XS
COLO-680N	NVGxOZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYGzUnRtUUN3ME2wMlg4QTN\|IN88US=>	NV:5[3ZDW0GQR1XS
NCI-H1581	NYXHR\|h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwOEmyPVch\|ryP	MmPCV2FPT0WU
HuCCT1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwOEm1OFgh\|ryP	Mo\oV2FPT0WU
BB30-HNC	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3iyeGlEPTB;MD65NlQ3QSEQvF2=	M4qxdHNCVkeHUh?=
NCI-H2347	NFfPTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PFXmlEPTB;MD65N\|I6OiEQvF2=	NUP1[YxEW0GQR1XS
G-401	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwOUO2PVUh\|ryP	MXPTRW5ITVJ?
NCI-H358	NUDlfHNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fvTmlEPTB;MD65OVAyPCEQvF2=	MW\TRW5ITVJ?
HCC1395	NXfG[llkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmD1TWM2OD1yLkm1OFYyKM7:TR?=	MVvTRW5ITVJ?
J82	NVHybJcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrlTWM2OD1yLkm1OVQ{KM7:TR?=	MXHTRW5ITVJ?
KE-37	NH23[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIW4UmpKSzVyPUCuPVY{QDdizszN	NW[wcGRxW0GQR1XS
NOMO-1	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwOU[1OlQh\|ryP	MYXTRW5ITVJ?
ML-2	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwOUm3OUDPxE1?	M1riT3NCVkeHUh?=
SW872	NIPRfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG3SllKSzVyPUCuPVk4PzVizszN	NHnibm9USU6JRWK=
KYSE-520	NVPVdVlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFwMEC0PVQh\|ryP	MofDV2FPT0WU
HL-60	M1PHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fwNmlEPTB;MT6wNFk4KM7:TR?=	M4\N[XNCVkeHUh?=
HDLM-2	NFT4ZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjxd2Y5UUN3ME2xMlAyOjV{IN88US=>	NHrF[GVUSU6JRWK=
MIA-PaCa-2	M4fmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:yTWM2OD1zLkCxN\|c2KM7:TR?=	MmfnV2FPT0WU
TCCSUP	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\XNVZKSzVyPUGuNFE4OzJizszN	MUTTRW5ITVJ?
SH-4	NH7ZeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL0XZR[UUN3ME2xMlAzOjR2IN88US=>	MnXwV2FPT0WU
MG-63	NVHIflZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\zZmNKSzVyPUGuNFI3OTZizszN	NV;YZ2MyW0GQR1XS
NB6	M4foXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf4eWFsUUN3ME2xMlA{OTB7IN88US=>	MXfTRW5ITVJ?
CAL-54	NGjh[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\yN\|lKSzVyPUGuNFM6PTlizszN	MlzNV2FPT0WU
DU-145	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17PcGlEPTB;MT6wPFA4OyEQvF2=	M1m5NHNCVkeHUh?=
HCE-4	NEnXXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\OdmlEPTB;MT6wPVI5PiEQvF2=	NFOySo5USU6JRWK=
U-266	NWD4S5AxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPkW2puUUN3ME2xMlA6PjN\|IN88US=>	MVTTRW5ITVJ?
HT-1197	NEPkR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;QenExUUN3ME2xMlEyPDN6IN88US=>	NVHIS4lqW0GQR1XS
EW-1	M2DTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzLbZNKSzVyPUGuNVQyOjhizszN	MoXrV2FPT0WU
MHH-NB-11	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDINVNuUUN3ME2xMlE2OzZ6IN88US=>	MU\TRW5ITVJ?
NCI-H2405	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrOTWM2OD1zLkG2NVYh\|ryP	M1HTVXNCVkeHUh?=
COLO-668	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUSwbIRTUUN3ME2xMlE3PDlizszN	MmrlV2FPT0WU
IMR-5	M4XEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkWwTWM2OD1zLkG2PVM3KM7:TR?=	NHnTTGlUSU6JRWK=
ARH-77	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XONmlEPTB;MT6yNlkzPCEQvF2=	NID1WFBUSU6JRWK=
BHT-101	NWfNc3BFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfPTWM2OD1zLkKzOFkh\|ryP	MnvNV2FPT0WU
SCC-25	NHnuVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3pTWM2OD1zLkKzOVM3KM7:TR?=	NIeyc21USU6JRWK=
NTERA-S-cl-D1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzlVm5KSzVyPUGuNlQ{PDZizszN	NFTlSYlUSU6JRWK=
MKN28	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwMkW2N\|Yh\|ryP	NEPLTYJUSU6JRWK=
KS-1	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PYXmlEPTB;MT6yPFI3QSEQvF2=	NYfmVFZ5W0GQR1XS
NCI-H1734	NXewVpFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;FOJdKSzVyPUGuNlg6OTNizszN	NX3SZ3pXW0GQR1XS
ES7	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfCb5pKSzVyPUGuNlk2PDJizszN	MYnTRW5ITVJ?
NCI-H838	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTyb\|YxUUN3ME2xMlMxPjF3IN88US=>	MYPTRW5ITVJ?
HEC-1	Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\GTWM2OD1zLkOzO\|U2KM7:TR?=	MVfTRW5ITVJ?
ME-180	NH;5[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfXfo1KSzVyPUGuN\|c6QTNizszN	MnrPV2FPT0WU
MMAC-SF	NWX5cHl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHmwcllKSzVyPUGuN\|k2QTVizszN	NYLCPWZJW0GQR1XS
IA-LM	M{m3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\uTGVKSzVyPUGuOFA6OTRizszN	NW\KTVUzW0GQR1XS
MN-60	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXiyeFJEUUN3ME2xMlQ{OTF2IN88US=>	NHyyOJlUSU6JRWK=
SIMA	M3zRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Pob2lEPTB;MT60PFY5PyEQvF2=	NGLod5ZUSU6JRWK=
NCI-H1770	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXQ[IF4UUN3ME2xMlUzODV2IN88US=>	M1jQWnNCVkeHUh?=
ONS-76	M4HiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTFwNUKzNVEh\|ryP	MUjTRW5ITVJ?
LB771-HNC	NYrtO4x{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTFwNUO5NFYh\|ryP	M3fhO3NCVkeHUh?=
SW48	NIfw[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[yTWM2OD1zLkW0NlQ{KM7:TR?=	M1HBbHNCVkeHUh?=
KYSE-140	M1rDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPDVFlMUUN3ME2xMlU2PzRzIN88US=>	NYDVZmhVW0GQR1XS
SW626	M3TmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn72TWM2OD1zLkW4NVYh\|ryP	NGXyU\|VUSU6JRWK=
MC-CAR	M2roTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTFwNUi2OlMh\|ryP	NWfER5RmW0GQR1XS
D-336MG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPZTWM2OD1zLk[yPVQh\|ryP	M3m4S3NCVkeHUh?=
SK-MEL-3	M1W0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XXSGlEPTB;MT62N\|kxOiEQvF2=	NFTWb5NUSU6JRWK=
MHH-PREB-1	M2HBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorMTWM2OD1zLk[0OFc{KM7:TR?=	NVzPTmhbW0GQR1XS
Calu-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFwNkWzPFYh\|ryP	MX;TRW5ITVJ?
HCC1806	M1;3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwNk[2NVEh\|ryP	MUTTRW5ITVJ?
A101D	M2jQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XxO2lEPTB;MT62Olc5OSEQvF2=	NIDTeIVUSU6JRWK=
A704	M4K4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHr4bVVKSzVyPUGuOlg{OTFizszN	MoTBV2FPT0WU
LB831-BLC	M3jLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M136XWlEPTB;MT62PVg2PCEQvF2=	NY\WV5g3W0GQR1XS
RL95-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TkOmlEPTB;MT63NVQ3OyEQvF2=	NFWwOJlUSU6JRWK=
RPMI-2650	NFv3WZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvqTWM2OD1zLkeyO\|E6KM7:TR?=	NFTRZXhUSU6JRWK=
NH-12	NH\WeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTFwN{O0Nlch\|ryP	M2exTXNCVkeHUh?=
AGS	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2qzRmlEPTB;MT63OlM2QCEQvF2=	MnnzV2FPT0WU
NEC8	M3rITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTFwN{i5PVUh\|ryP	MmT1V2FPT0WU
NCI-H2009	M1r6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTFwN{m3NlEh\|ryP	MXPTRW5ITVJ?
A498	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PDZWlEPTB;MT64NVI5OiEQvF2=	M4faTXNCVkeHUh?=
NCI-H810	MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe1[FhKSzVyPUGuPFE3ODZizszN	MWXTRW5ITVJ?
SK-NEP-1	NWLmXJpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrEc\|k3UUN3ME2xMlg{PzZ5IN88US=>	MmOwV2FPT0WU
D-542MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7RTWM2OD1zLki1PFUyKM7:TR?=	MX\TRW5ITVJ?
KNS-42	NWPnNZFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDhTWM2OD1zLki2NlY3KM7:TR?=	M1T1Z3NCVkeHUh?=
NCI-H2452	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGG3OmNKSzVyPUGuPFkxPzRizszN	MVrTRW5ITVJ?
SK-MEL-2	NEXKbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwOUCyO\|Eh\|ryP	MoP6V2FPT0WU
OVCAR-5	NFf1fFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TDV2lEPTB;MT65NFY4PSEQvF2=	NWm4cWVOW0GQR1XS
SNG-M	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LOXGlEPTB;MT65OVg2QCEQvF2=	MYHTRW5ITVJ?
A673	NXnhTJl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwOUe1NVYh\|ryP	MU\TRW5ITVJ?
L-428	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTFwOUmxO\|kh\|ryP	NF\hRWFUSU6JRWK=
KM-H2	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvRZnlwUUN3ME2yMlAyODlizszN	M4PU[3NCVkeHUh?=
MC-IXC	M2ToSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXG4[lZZUUN3ME2yMlAzOjd\|IN88US=>	MmnGV2FPT0WU
COLO-678	NYHmXXNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\STWM2OD1{LkC0NlA4KM7:TR?=	M4T2Z3NCVkeHUh?=
MEL-JUSO	NV3EcZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\VNIt1UUN3ME2yMlA4QDVzIN88US=>	NXrQfWROW0GQR1XS
HCC38	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;VOmlEPTB;Mj6wPFQ{OyEQvF2=	MVjTRW5ITVJ?
UACC-62	M2HzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTJwMEi4OVUh\|ryP	NUTZVmExW0GQR1XS
OAW-42	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLvTWM2OD1{LkC5O\|EyKM7:TR?=	NEmyUlNUSU6JRWK=
LB996-RCC	NELjTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHDW3RKSzVyPUKuNVM5OTdizszN	M3;RSnNCVkeHUh?=
COR-L105	NX\JSJVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{noT2lEPTB;Mj6xOlM4OyEQvF2=	MnO5V2FPT0WU
RCC10RGB	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn5VmVKSzVyPUKuNVg2PzZizszN	NXPHeGMzW0GQR1XS
A431	NYe1SY1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTJwMUmwNVkh\|ryP	M4jLUHNCVkeHUh?=
NCI-H292	MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmS5TWM2OD1{LkKzPVUyKM7:TR?=	NV\1NZU6W0GQR1XS
SK-UT-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJwM{OxPFQh\|ryP	NUHoT\|czW0GQR1XS
PANC-08-13	NEPqelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fZV2lEPTB;Mj6zN\|I{PSEQvF2=	NWjidHVrW0GQR1XS
ST486	NFvwd\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXHTWM2OD1{LkSxNFQ5KM7:TR?=	Mki1V2FPT0WU
SJSA-1	NE\RTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHT5V\|VKSzVyPUKuOFEzPzFizszN	MWrTRW5ITVJ?
RKO	M{PndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTJwNEKwNlkh\|ryP	MUjTRW5ITVJ?
NCI-H1793	M2LuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P2SmlEPTB;Mj60OFAzQSEQvF2=	M{fEfHNCVkeHUh?=
639-V	NIq0cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTJwNEWzPFIh\|ryP	MWDTRW5ITVJ?
ES3	NITzWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTJwNEm3N\|ch\|ryP	NGTuWZdUSU6JRWK=
NCI-H1792	NVHGdot4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTJwNU[4NlYh\|ryP	MXTTRW5ITVJ?
NCI-H1651	NXi2[4d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvaRmhKSzVyPUKuOVgzOSEQvF2=	MUXTRW5ITVJ?
SN12C	M3XjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLzTWM2OD1{LkW4OFg4KM7:TR?=	MXzTRW5ITVJ?
COLO-679	NUK5dWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPjOVBKSzVyPUKuOVg3ODVizszN	MkT4V2FPT0WU
U-118-MG	NES4VYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTJwNUi4O\|Ih\|ryP	NXGyVVE4W0GQR1XS
Ramos-2G6-4C10	M3jBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnofXlKSzVyPUKuOlQ5ODdizszN	Ml;4V2FPT0WU
HCT-15	M3Xoemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PrdmlEPTB;Mj62PFc6OiEQvF2=	MWjTRW5ITVJ?
MDA-MB-157	MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3yd5BKSzVyPUKuO\|A4PDdizszN	NWHTenRpW0GQR1XS
K5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELFc5RKSzVyPUKuO\|E5PDVizszN	NWDabo1kW0GQR1XS
MKN45	M3HS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJwN{OzOlYh\|ryP	MnW4V2FPT0WU
DMS-273	NYHiS5l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfmeFdGUUN3ME2yMlc2PjN{IN88US=>	M{LZZnNCVkeHUh?=
C8166	NF7sV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnyTW4zUUN3ME2yMlc5PTF\|IN88US=>	NGPBcWRUSU6JRWK=
Calu-3	NXHGfJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{WwXGlEPTB;Mj63PFk3QSEQvF2=	Mn;JV2FPT0WU
SNB75	M4\ONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrhTWM2OD1{Lki4OVM2KM7:TR?=	Mn3XV2FPT0WU
BFTC-905	NWH2TlRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJwOUCxPVEh\|ryP	NYTaRY5nW0GQR1XS
C-4-II	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTJwOUGzOVMh\|ryP	MoXwV2FPT0WU
MS-1	NF;wRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HzUGlEPTB;Mj65Olc3QSEQvF2=	MnnwV2FPT0WU
A375	NIS5WVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNwMEixPFQh\|ryP	M2[4c3NCVkeHUh?=
KYSE-70	MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTTTWM2OD1\|LkC4PFgzKM7:TR?=	M3voRXNCVkeHUh?=
KYSE-510	NHzIPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXZTWM2OD1\|LkGwPVk2KM7:TR?=	MlfSV2FPT0WU
LN-405	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHWSW1bUUN3ME2zMlE{PTF6IN88US=>	NILNbYxUSU6JRWK=
BOKU	M4\tW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7STWM2OD1\|LkG0NlU3KM7:TR?=	MUDTRW5ITVJ?
TE-10	M3XJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\xTWM2OD1\|LkG3N\|YzKM7:TR?=	NWTFUGhxW0GQR1XS
MKN1	NGXmN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\6UGlEPTB;Mz6xPFQ5OyEQvF2=	M1eye3NCVkeHUh?=
M059J	NUfFVZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f4S2lEPTB;Mz6yNFE4OyEQvF2=	NVnod5htW0GQR1XS
GOTO	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWG5Xo9MUUN3ME2zMlIzODN7IN88US=>	MX;TRW5ITVJ?
DK-MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTNwMkW5O\|Yh\|ryP	Mlm5V2FPT0WU
NCI-H727	M1fEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInXdJlKSzVyPUOuNlY2QCEQvF2=	NETZdI9USU6JRWK=
NB12	M4mxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHix[HhKSzVyPUOuN\|MzOjRizszN	NF;wWYdUSU6JRWK=
DOK	M3i2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zTeGlEPTB;Mz6zOlE5PiEQvF2=	NFXTWoFUSU6JRWK=
KYSE-410	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jqZmlEPTB;Mz6zOlI5PyEQvF2=	M4PYd3NCVkeHUh?=
AM-38	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjBfGlpUUN3ME2zMlM5ODVzIN88US=>	MkHtV2FPT0WU
GR-ST	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnw[\|FTUUN3ME2zMlQ2PzN{IN88US=>	NGmxWVhUSU6JRWK=
D-247MG	NFLJfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Txc2lEPTB;Mz60PFI3OyEQvF2=	NUnCOYd3W0GQR1XS
TE-8	NX\JXFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTNwNEmzN\|Mh\|ryP	MkLYV2FPT0WU
LS-411N	NF7FT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DKbmlEPTB;Mz60PVY6OiEQvF2=	NUDaRXdyW0GQR1XS
SK-MES-1	NYHifWRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3MTWM2OD1\|LkW2OFM{KM7:TR?=	NFPqVolUSU6JRWK=
SF295	NV[xbppuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfxNmtYUUN3ME2zMlYyPTV{IN88US=>	Ml35V2FPT0WU
SK-MEL-30	NFTFZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTNwNkW5NlEh\|ryP	MVzTRW5ITVJ?
LB2241-RCC	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTYTY9KSzVyPUOuOlYzPiEQvF2=	MnvuV2FPT0WU
PC-14	NIPBbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFG0boJKSzVyPUOuOlY1OzdizszN	MULTRW5ITVJ?
EW-7	NHPPSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIL5e3hKSzVyPUOuOlc3QTNizszN	NWHOSoRlW0GQR1XS
NMC-G1	NW\0bWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2j2PWlEPTB;Mz63NVg{PyEQvF2=	MUnTRW5ITVJ?
TE-441-T	M4\JPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPjTWM2OD1\|LkezNFI5KM7:TR?=	NIL1PIdUSU6JRWK=
NCI-H1618	NVXrd3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXw[4RKSzVyPUOuPFE5PzVizszN	NUf2OmkxW0GQR1XS
PANC-03-27	MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nXTGlEPTB;Mz64NVkyPiEQvF2=	M2fKVXNCVkeHUh?=
NCI-H2228	NWPJdYN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3DVmdnUUN3ME2zMlg{OTJ4IN88US=>	M4C4bHNCVkeHUh?=
CAPAN-1	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrIPHpKSzVyPUOuPFcxODlizszN	NFe0RWtUSU6JRWK=
KLE	NYnBelExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnPTpFKSzVyPUOuPVA3PyEQvF2=	MVXTRW5ITVJ?
Becker	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fGXWlEPTB;Mz65Nlg1QSEQvF2=	Mom3V2FPT0WU
SK-PN-DW	NYS3XoM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTRwMEe5O\|Qh\|ryP	NYrjdnVkW0GQR1XS
Hs-578-T	M4THVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HofGlEPTB;ND6wPFMxPiEQvF2=	NF\ndGdUSU6JRWK=
RS4-11	NIn0bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjXR2VwUUN3ME20MlEyOjV3IN88US=>	MY\TRW5ITVJ?
D-502MG	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTRwMU[5PVch\|ryP	MkDSV2FPT0WU
GI-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{X0O2lEPTB;ND6yPFI6QSEQvF2=	MmjqV2FPT0WU
NCI-H209	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV30T3pEUUN3ME20MlM{PzhizszN	Ml7kV2FPT0WU
SK-OV-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLmN3BuUUN3ME20MlQ5OTR7IN88US=>	M4fncnNCVkeHUh?=
LOUCY	NIjhXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TVXmlEPTB;ND60PFQ{OiEQvF2=	M{Ox[HNCVkeHUh?=
NCI-H69	M3LPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkj2TWM2OD12LkWxO\|k{KM7:TR?=	MVTTRW5ITVJ?
SCC-9	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlG2TWM2OD12LkWzNVczKM7:TR?=	NV;oOldvW0GQR1XS
NCI-H526	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLITWM2OD12LkW5Nlk{KM7:TR?=	M{LPbHNCVkeHUh?=
NCI-H2170	M3O2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTRwNk[3O\|Eh\|ryP	MmLrV2FPT0WU
SR	NX:0fIxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnf3TWM2OD12LkewNFQ5KM7:TR?=	MVrTRW5ITVJ?
CMK	Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TtSWlEPTB;ND63NlExOSEQvF2=	NHLhWmZUSU6JRWK=
COLO-829	NYL1PGJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTRwN{ewOFMh\|ryP	NXHZXVB2W0GQR1XS
HuO-3N1	NGDDXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmCyTWM2OD12LkizNlgyKM7:TR?=	MWnTRW5ITVJ?
5637	M3nqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXz1eGNxUUN3ME20MlkxPDh5IN88US=>	MnS4V2FPT0WU
A253	NEGzOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mln2TWM2OD12Lkm3O\|A5KM7:TR?=	NWnZcphWW0GQR1XS
NB10	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTFUnhKSzVyPUWuNFc1QTdizszN	MVjTRW5ITVJ?
SF539	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrFRYljUUN3ME21MlA6QTV7IN88US=>	NWn1RlFOW0GQR1XS
HAL-01	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTVwMUS2OFUh\|ryP	NFXadW9USU6JRWK=
MHH-ES-1	NV7DOmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\UR\|NKSzVyPUWuNVY6OjVizszN	NHfoNGlUSU6JRWK=
DEL	NYPT[GJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnZTWM2OD13LkK3OVgzKM7:TR?=	MYnTRW5ITVJ?
NCI-H1299	M33Y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HiZWlEPTB;NT6zOVAxPyEQvF2=	MV\TRW5ITVJ?
ChaGo-K-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\GeXJKSzVyPUWuN\|UyODdizszN	NH;mVm1USU6JRWK=
HMV-II	NXf4SnFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTWTWM2OD13LkO5OFMh\|ryP	NUH4TXhLW0GQR1XS
NB69	M1PvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFznelRKSzVyPUWuN\|k3OzFizszN	MXTTRW5ITVJ?
NCI-H1882	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTVwNEOzOlQh\|ryP	NVz5TXVrW0GQR1XS
SNU-475	NV3YZVk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED3TI1KSzVyPUWuOFcyPzFizszN	M4K0PHNCVkeHUh?=
RXF393	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\R[VY5UUN3ME21MlQ5PDl2IN88US=>	MmqzV2FPT0WU
CAL-51	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlmwTWM2OD13Lk[yPFU{KM7:TR?=	NUnqN3h7W0GQR1XS
SW1573	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPJdldKSzVyPUWuOlM2OzRizszN	NWPOU3V3W0GQR1XS
GCT	M{jOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGO1eIZKSzVyPUWuO\|U6OjlizszN	MVHTRW5ITVJ?
COR-L88	NWjjN5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHoTWM2OD13Lke2PFQ3KM7:TR?=	M13yd3NCVkeHUh?=
MDA-MB-134-VI	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnnU4pKSzVyPUWuPFc2OzZizszN	MlnJV2FPT0WU
NB5	NVvP[Fh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vTVWlEPTB;NT65NlQ1KM7:TR?=	NVHHOpdkW0GQR1XS
GMS-10	NXOyc4JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3T5bmlEPTB;NT65Olg3OSEQvF2=	NXPDOppVW0GQR1XS
CHP-212	NGfjWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVf0ZmZsUUN3ME22MlQ5OjZ5IN88US=>	M3vYdHNCVkeHUh?=
TE-11	NUfD[HFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPGcnZRUUN3ME22MlU2OTh{IN88US=>	MlTBV2FPT0WU
SW962	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS2NI05UUN3ME22MlY2Pzd2IN88US=>	M4fQSXNCVkeHUh?=
MZ2-MEL	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fmNWlEPTB;Nj64NlAyOSEQvF2=	M2Ds[3NCVkeHUh?=
C-33-A	NHLQcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXnXWZvUUN3ME22MlkyPjh6IN88US=>	MV3TRW5ITVJ?
IGR-1	M4S1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTZwOUe4NlYh\|ryP	NEGySFhUSU6JRWK=
MOLT-4	NXS5eXMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDqZ3NKSzVyPUeuNVU1ODZizszN	M3vSbXNCVkeHUh?=
NCI-H1650	MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{W4Z2lEPTB;Nz6yO\|A1PiEQvF2=	NX7GZWVHW0GQR1XS
AsPC-1	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEO3d5dKSzVyPUeuNlg3ODVizszN	NVni[FB1W0GQR1XS
SNU-C2B	MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGqwNnVKSzVyPUeuNlk2PzFizszN	M{TtU3NCVkeHUh?=
MKN7	NEO2N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmH1TWM2OD15LkO3NlM2KM7:TR?=	Mn;DV2FPT0WU
SW620	NUL2ZmZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTdwM{iyNFUh\|ryP	NGPUVHhUSU6JRWK=
SK-MEL-28	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTqUmEyUUN3ME23MlQxPzl6IN88US=>	MlG3V2FPT0WU
TE-6	MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHiSmlKSzVyPUeuOFQ6ODhizszN	NVLBb5pxW0GQR1XS
D-263MG	NIro[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjRPFNxUUN3ME23MlQ2PzZ{IN88US=>	MlTLV2FPT0WU
NCI-H1355	NGXPOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfHTWM2OD15Lke3NFI6KM7:TR?=	M1nQe3NCVkeHUh?=
DSH1	MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfOblhVUUN3ME23Mlc6PzZ{IN88US=>	NEfZSI1USU6JRWK=
NCI-H460	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHpfpNYUUN3ME24MlAxPjl2IN88US=>	NIPnUllUSU6JRWK=
NCI-H1563	NEj3SohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ix[mlEPTB;OD6wO\|UxQCEQvF2=	M{nCZXNCVkeHUh?=
SW948	M3Pv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIWzcYlKSzVyPUiuNVA4PDRizszN	NWHKcJdvW0GQR1XS
LK-2	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfvSlVvUUN3ME24MlEzQDN\|IN88US=>	NHHnbZBUSU6JRWK=
HT-1080	M1uzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRThwMUOxO\|Uh\|ryP	MX\TRW5ITVJ?
NCI-H441	M{DNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmSzTWM2OD16LkG5N{DPxE1?	Mlu2V2FPT0WU
HSC-4	M4PzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rhRmlEPTB;OD6yPFczKM7:TR?=	NHXNbZFUSU6JRWK=
LXF-289	MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\vTWM2OD16LkO1PVQ{KM7:TR?=	M4fJSnNCVkeHUh?=
MRK-nu-1	M3fRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOzW3NKSzVyPUiuN\|Y{ODRizszN	MoHVV2FPT0WU
no-11	M4C3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVH5d5Y6UUN3ME24MlQ4OTN\|IN88US=>	NEnIdlRUSU6JRWK=
SNU-387	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRThwNkOyOFYh\|ryP	NE\aNIFUSU6JRWK=
Detroit562	NInQTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PPemlEPTB;OD63OVQ2PSEQvF2=	MUXTRW5ITVJ?
SW954	M1K4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFezW3dKSzVyPUiuO\|Y5OzJizszN	MUfTRW5ITVJ?
P12-ICHIKAWA	NF;3dXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moj1TWM2OD16Lke4PVQh\|ryP	M2e1dnNCVkeHUh?=
TE-9	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TtdmlEPTB;OD64NVA3OiEQvF2=	M1rDXXNCVkeHUh?=
NB13	NHG4bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;yRmlEPTB;OD64N\|c6PiEQvF2=	NGLldFdUSU6JRWK=
BPH-1	M3Pne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRThwOEWwPFEh\|ryP	MkPVV2FPT0WU
KMOE-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVH5VnF[UUN3ME24Mlg4QDl{IN88US=>	NEHXPZdUSU6JRWK=
RPMI-8402	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LENmlEPTB;OD64PVkzPiEQvF2=	NXrMd5NiW0GQR1XS
OVCAR-3	NHTSUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn5TWM2OD16Lkm3O\|MzKM7:TR?=	NWW3R5pxW0GQR1XS
NCI-H2196	NIT6c4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnCcW0zUUN3ME24Mlk5PjB4IN88US=>	NXHIPXRyW0GQR1XS
MZ7-mel	M3vGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFe1cIhKSzVyPUmuNFM1PiEQvF2=	M4K0bHNCVkeHUh?=
GP5d	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTlwME[zNVMh\|ryP	MYjTRW5ITVJ?
NCI-N87	NWm0SHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4j0[GlEPTB;OT60OFc{OSEQvF2=	MoP3V2FPT0WU
EW-16	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nJfWlEPTB;OT60OFg1QCEQvF2=	NVTqN2NXW0GQR1XS
Calu-6	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jEOmlEPTB;OT60PVcxOyEQvF2=	M4XrT3NCVkeHUh?=
LC4-1	NFvKTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTK[mN2UUN3ME25MlYzPTdizszN	NGjL[GxUSU6JRWK=
CCRF-CEM	NHzvdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW[wdGZGUUN3ME25MlY5PzZ4IN88US=>	M4jUfnNCVkeHUh?=
BC-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTlwN{i5PUDPxE1?	Mn;xV2FPT0WU
NCI-SNU-16	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDlTWM2OD17Lke5OFk2KM7:TR?=	MVTTRW5ITVJ?
NCI-H28	NVTUNmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfleZdKSzVyPUmuPFQ6OzNizszN	NHfWclZUSU6JRWK=
SBC-1	M33mbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLJT4pKSzVyPUGwMlA4OiEQvF2=	NFPXXFdUSU6JRWK=
TUR	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Ubpo5UUN3ME2xNE4yPjV5IN88US=>	NFP1em1USU6JRWK=
MDA-MB-231	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jYR2lEPTB;MUCuNlEyPCEQvF2=	M{nufHNCVkeHUh?=
C3A	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULGUJh1UUN3ME2xNE4{OTd7IN88US=>	MoriV2FPT0WU
SW1990	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX32[W9CUUN3ME2xNE4{OjhizszN	MUXTRW5ITVJ?
NCI-H1993	NIS3TXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mof3TWM2OD1zMD61Olk{KM7:TR?=	NF\2XY9USU6JRWK=
SK-CO-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnlW2RsUUN3ME2xNE44PzdizszN	M2H1e3NCVkeHUh?=
OAW-28	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2r0c2lEPTB;MUCuPVg5QCEQvF2=	MWHTRW5ITVJ?
HN	M4fRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TOSWlEPTB;MUGuNVE{OSEQvF2=	MkjkV2FPT0WU
NCI-H1304	M1;COmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\MfYhKSzVyPUGxMlE2PzZizszN	MVPTRW5ITVJ?
Daoy	NI[1dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf3W4tKSzVyPUGxMlQ{OzZizszN	NEPNdo1USU6JRWK=
VA-ES-BJ	NH;RRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XxNGlEPTB;MUGuO\|E6PSEQvF2=	MX3TRW5ITVJ?
MCF7	NWLuO3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTFzLkixNlYh\|ryP	Mlz2V2FPT0WU
VM-CUB-1	NF7ac2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTFzLkmwPVEh\|ryP	M3;rTXNCVkeHUh?=
IPC-298	NHfXdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFzLkmzPFMh\|ryP	MmDMV2FPT0WU
NCI-H2126	M4LYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrLfVRGUUN3ME2xNk4xOjF6IN88US=>	MmS1V2FPT0WU
OVCAR-8	NHO2cIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTF{LkGxOFEh\|ryP	NIXvcW1USU6JRWK=
SJRH30	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnvepBKSzVyPUGyMlIzQTlizszN	NVPScmNFW0GQR1XS
DMS-53	Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\ZWo01UUN3ME2xNk4zPjR7IN88US=>	M37aWHNCVkeHUh?=
NCI-H322M	NVPwbG1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDWe285UUN3ME2xNk4{OzV5IN88US=>	M4m0cHNCVkeHUh?=
RVH-421	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3wTHlKSzVyPUGyMlQ6ODRizszN	M{TSOXNCVkeHUh?=
Raji	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2q5XWlEPTB;MUKuOlE1KM7:TR?=	MUXTRW5ITVJ?
MDA-MB-415	M1r3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTF{Lk[0OFQh\|ryP	Mn7UV2FPT0WU
EFE-184	NGf4VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4POdmlEPTB;MUKuO\|ExPiEQvF2=	M3;nbHNCVkeHUh?=
BFTC-909	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTF{LkmyOFch\|ryP	MkOzV2FPT0WU
BHY	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nyNGlEPTB;MUOuN\|M6KM7:TR?=	NXPnVpd[W0GQR1XS
YKG-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTF\|LkO3OFkh\|ryP	M1:3THNCVkeHUh?=
EW-3	M1njemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\HTWM2OD1zMz63NVY{KM7:TR?=	NFvOfHFUSU6JRWK=
HCC1143	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTF\|Lke0N\|ch\|ryP	NE\GRZpUSU6JRWK=
REH	M4\WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoO2TWM2OD1zMz64PVgzKM7:TR?=	MmjoV2FPT0WU
CESS	M1TadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTF\|Lkm0PFkh\|ryP	MWXTRW5ITVJ?
EFM-19	NIP2dJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rRNGlEPTB;MUSuNVEyOiEQvF2=	NWq1TJRCW0GQR1XS
U031	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLmSm85UUN3ME2xOE41ODh3IN88US=>	MlLIV2FPT0WU
ES1	MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXqfIxKSzVyPUG0MlQ5PTFizszN	MnPOV2FPT0WU
HSC-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjvNW9KSzVyPUG0MlYzOTVizszN	NEPTfG1USU6JRWK=
LOXIMVI	M3fk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TSXGlEPTB;MUSuO\|A3QCEQvF2=	NGLGU4xUSU6JRWK=
A388	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n2R2lEPTB;MUSuO\|U2PiEQvF2=	MYDTRW5ITVJ?
KP-N-YS	NVrRTW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF2Lke3N{DPxE1?	NWrpOoJ4W0GQR1XS
Capan-2	NXfRXW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;uTWM2OD1zND63PFYh\|ryP	MoLtV2FPT0WU
SKG-IIIa	NUTWS\|kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml75TWM2OD1zND64PFYzKM7:TR?=	MXXTRW5ITVJ?
HEL	NXLpUlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PYWWlEPTB;MUSuPFk6PyEQvF2=	M{fHd3NCVkeHUh?=
BEN	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTF2Lkm3OlYh\|ryP	NGnxXo9USU6JRWK=
MC116	M1P2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvoVYJ6UUN3ME2xOU4yPTl7IN88US=>	M{TjeXNCVkeHUh?=
IGROV-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTF3LkKzNVch\|ryP	Moe1V2FPT0WU
NCI-H1648	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTF3LkWzNFUh\|ryP	MmKzV2FPT0WU
ABC-1	NWXpbpk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PuWGlEPTB;MUWuPFA{OyEQvF2=	NEj5VWVUSU6JRWK=
EW-18	NELTSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDkTWM2OD1zNT65PVc6KM7:TR?=	NFvj[2JUSU6JRWK=
BC-3	M{PLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXHWpdMUUN3ME2xOk4xPTZ{IN88US=>	M4nXOXNCVkeHUh?=
NCI-H1437	NYGyb2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTF4LkC2Olch\|ryP	M1;vR3NCVkeHUh?=
SCC-15	NF\McGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\DTWM2OD1zNj6yPFI2KM7:TR?=	M{\6OXNCVkeHUh?=
TT	NWC2cY06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\BcGlEPTB;MU[uOVg5QCEQvF2=	M{PoU3NCVkeHUh?=
KINGS-1	NHzn[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnnNFZzUUN3ME2xOk45Ojd\|IN88US=>	NVziWWpMW0GQR1XS
C32	NIXDRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojZTWM2OD1zNj65O\|E4KM7:TR?=	MXPTRW5ITVJ?
SBC-5	M3XUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPzTpJ1UUN3ME2xO{4yPDd7IN88US=>	NHj4[m1USU6JRWK=
NB1	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXmzOYxqUUN3ME2xO{4{OTh6IN88US=>	NV\Wd3U1W0GQR1XS
EB-3	M1r5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWP5XlVRUUN3ME2xO{42PzZizszN	MYfTRW5ITVJ?
NCI-H748	NVj2TWRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTF5LkewN\|Uh\|ryP	NHjHTFJUSU6JRWK=
IST-SL1	NInU[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrWZWtKSzVyPUG3Mlc2OjZizszN	M13XWnNCVkeHUh?=
WM-115	M{nJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjnN3pKSzVyPUG3MlgxQDVizszN	M4G4bHNCVkeHUh?=
NCI-H226	NGHkdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTF5Lkm1OFYh\|ryP	NULkUm5kW0GQR1XS
CAL-33	NIfIZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17CWGlEPTB;MUiuNlc5OSEQvF2=	NEXwRZNUSU6JRWK=
SCC-4	M3rJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Xh[WlEPTB;MUiuN\|IzQSEQvF2=	MWTTRW5ITVJ?
RMG-I	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPY[3ZKSzVyPUG4MlY6PDdizszN	NIXyN\|dUSU6JRWK=
KOSC-2	NX\LToNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn33TWM2OD1zOD63O\|Q3KM7:TR?=	MVXTRW5ITVJ?
A2058	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHaTWM2OD1zOD64NlU2KM7:TR?=	NYr4UWVFW0GQR1XS
HCC70	M3faTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml62TWM2OD1zOT6zPFk1KM7:TR?=	M2TU[nNCVkeHUh?=
C2BBe1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Thd2lEPTB;MUmuOFE1QCEQvF2=	M2mx[XNCVkeHUh?=
NCI-H650	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFSyWW1KSzVyPUG5MlU5QTlizszN	MUjTRW5ITVJ?
CAL-72	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfuTWM2OD1zOT62O\|M4KM7:TR?=	MmrTV2FPT0WU
L-363	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XxU2lEPTB;MkCuNFIyOiEQvF2=	MXTTRW5ITVJ?
SNU-423	NXXMT\|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTJyLkGwOFMh\|ryP	MlP4V2FPT0WU
PLC-PRF-5	M16xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYruNJhGUUN3ME2yNE4{QTB4IN88US=>	NUn1PFdSW0GQR1XS
SW1463	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVexe2xOUUN3ME2yNE41PTJ3IN88US=>	M2DG[3NCVkeHUh?=
769-P	NIe3RllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnqyTWM2OD1{MD62O\|Y6KM7:TR?=	MULTRW5ITVJ?
DMS-79	NHS3WItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzyNnJGUUN3ME2yNE45PDlizszN	NWfVb3l[W0GQR1XS
Saos-2	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TZUmlEPTB;MkCuPVU2PiEQvF2=	NFzxTI5USU6JRWK=
CHP-126	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHZUWhKSzVyPUKxMlQ1PjJizszN	M3e4enNCVkeHUh?=
SW837	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TkWGlEPTB;MkGuOFk{QSEQvF2=	NU[5NGtnW0GQR1XS
SHP-77	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfBVZZKSzVyPUKxMlYyOjJizszN	NFzYb5NUSU6JRWK=
DB	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTJzLk[xOFIh\|ryP	NGPaO49USU6JRWK=
ES5	NVHNV4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTJzLk[4OlQh\|ryP	MVHTRW5ITVJ?
COR-L23	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jvUGlEPTB;MkGuPFA2OSEQvF2=	NV\EU2FkW0GQR1XS
KU-19-19	NIH0TmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;VepRKSzVyPUKxMlg6QDJizszN	M4rsfHNCVkeHUh?=
T84	NUTOfXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XQTGlEPTB;MkGuPVgyQSEQvF2=	NVnzbVNpW0GQR1XS
NCI-H630	NGfkXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTJ{LkWzOlMh\|ryP	NWPqTGxuW0GQR1XS
LU-165	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHQfolKSzVyPUKyMlU2PCEQvF2=	NFvkZYlUSU6JRWK=
COLO-792	Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTJ{LkexNVEh\|ryP	M4LjPXNCVkeHUh?=
CAL-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTJ{Lke1NVch\|ryP	M3rUeHNCVkeHUh?=
HCE-T	NWTrVIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTJ{Lki2NFYh\|ryP	NGj2fm9USU6JRWK=
BB65-RCC	NYjtNVJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1qwWGlEPTB;MkOuNFM1PCEQvF2=	M4XrSHNCVkeHUh?=
SiHa	NGPqbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnVXGtDUUN3ME2yN{4{QTZ6IN88US=>	MV;TRW5ITVJ?
NCI-H2081	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTJ2LkC2OFEh\|ryP	MkXYV2FPT0WU
U251	NVTRe5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTrTWM2OD1{ND6wOlY5KM7:TR?=	MX3TRW5ITVJ?
LoVo	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\KUGlEPTB;MkSuPVI5OiEQvF2=	MkDoV2FPT0WU
GCIY	M376Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTtTWM2OD1{NT6yPFc4KM7:TR?=	MlvtV2FPT0WU
NUGC-3	M2jXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTJ3LkOzNVYh\|ryP	M1fOR3NCVkeHUh?=
LNCaP-Clone-FGC	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TxVWlEPTB;MkWuN\|Q6QCEQvF2=	MoDTV2FPT0WU
PA-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\4TWM2OD1{NT62PFM{KM7:TR?=	MU\TRW5ITVJ?
OE33	NIfLV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrSWmU5UUN3ME2yOU43QDV\|IN88US=>	M3q3Z3NCVkeHUh?=
HT-29	NWLwUW43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\SeZRKSzVyPUK1Mlc5PzlizszN	MkTKV2FPT0WU
RCM-1	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;HW5NOUUN3ME2yOU46PjV4IN88US=>	NFft[XRUSU6JRWK=
NCI-H1522	M3KwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PPTWlEPTB;MkWuPVkyOSEQvF2=	NUjIWpBoW0GQR1XS
LB373-MEL-D	NG\qRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPnTWM2OD1{Nj6xO\|A5KM7:TR?=	MoPuV2FPT0WU
NCI-H1436	M1vTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJ4LkK3N\|gh\|ryP	MX3TRW5ITVJ?
COLO-824	NVziWHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLWTWM2OD1{Nj60NFAzKM7:TR?=	MWHTRW5ITVJ?
CP50-MEL-B	NV;MVYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PqTmlEPTB;Mk[uOVY4PSEQvF2=	NVfFXlhlW0GQR1XS
EGI-1	NFexWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPLS\|lKSzVyPUK3MlI3QThizszN	NIr2ZoNUSU6JRWK=
LAN-6	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PUb2lEPTB;MkeuN\|U6QCEQvF2=	MYTTRW5ITVJ?
GAK	M3fSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJ5LkSyNlUh\|ryP	MkHZV2FPT0WU
MDA-MB-175-VII	MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXpTWM2OD1{Nz61NFU{KM7:TR?=	M1HhTnNCVkeHUh?=
JVM-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnPTWM2OD1{Nz62OlIzKM7:TR?=	MnjGV2FPT0WU
UACC-257	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLpTWM2OD1{Nz62PFc5KM7:TR?=	MmTXV2FPT0WU
SW1783	M13xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;3UGFqUUN3ME2yO{44Pzh\|IN88US=>	MWTTRW5ITVJ?
HT-3	NFPLZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTJ6LkKxOlYh\|ryP	Ml3WV2FPT0WU
RL	NX7IfHN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\zTZFKSzVyPUK4MlU6OTFizszN	NIn2PZZUSU6JRWK=
TK10	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLIeZo{UUN3ME2yPE43PTN3IN88US=>	Mof5V2FPT0WU
HT55	NXGy[5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXq5NlFjUUN3ME2yPU4xPTZ3IN88US=>	NWjmN3VnW0GQR1XS
BT-20	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHVTWM2OD1{OT6wOVg3KM7:TR?=	M4PsfXNCVkeHUh?=
TGBC24TKB	NF\mSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:4SWlEPTB;MkmuNVg{OSEQvF2=	NGjFU5FUSU6JRWK=
HSC-2	NFTCdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrKb2hKSzVyPUK5MlMxODFizszN	NXjzVVBrW0GQR1XS
COLO-205	M2TDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJ7LkO5OFQh\|ryP	MVfTRW5ITVJ?
GT3TKB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTJ7Lk[4O\|ch\|ryP	MWrTRW5ITVJ?
T47D	NVSyeZdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nrTmlEPTB;MkmuPFU5OiEQvF2=	NETLWIxUSU6JRWK=
OMC-1	NUfvcoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYniZ5N5UUN3ME2zNE4yQTF7IN88US=>	M{GxTXNCVkeHUh?=
PFSK-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX0Wm9xUUN3ME2zNU4zPjV7IN88US=>	MYfTRW5ITVJ?
JEG-3	M2fiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXrTWM2OD1\|MT6zOVYyKM7:TR?=	M4HZU3NCVkeHUh?=
RD	NFHQcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnMTWM2OD1\|MT61NVE2KM7:TR?=	NUTXNGxnW0GQR1XS
NCI-H64	NXLJNpYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTN{LkSxO\|kh\|ryP	NHr4[FhUSU6JRWK=
DMS-114	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGiyfIVKSzVyPUOyMlQyQDJizszN	MlSxV2FPT0WU
NCI-H661	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;qfmlEPTB;M{KuOlUxOSEQvF2=	MUjTRW5ITVJ?
CAL-148	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL4Xnd6UUN3ME2zNk43PjZ3IN88US=>	NUizRoE3W0GQR1XS
HuP-T3	M1zuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXz6WYNQUUN3ME2zNk46OzN6IN88US=>	NWfobHpqW0GQR1XS
ES4	NFvUOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTN\|LkG3NFUh\|ryP	Mk\RV2FPT0WU
Ca9-22	NF6yd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M324VmlEPTB;M{OuOFYxOSEQvF2=	NH73UVlUSU6JRWK=
LP-1	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDKTWM2OD1\|ND6wPUDPxE1?	MnPEV2FPT0WU
AU565	M3Tybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTN2LkWwOlkh\|ryP	Mli1V2FPT0WU
MDA-MB-453	NF:yPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrGR3MyUUN3ME2zOU4yPDJ4IN88US=>	M{PkVXNCVkeHUh?=
SNU-C1	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPafFFUUUN3ME2zOU4yPzFizszN	MkDXV2FPT0WU
SW13	NXjrTW44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTN3LkSwO\|Yh\|ryP	NFKyUXJUSU6JRWK=
NCI-H2122	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXniT3VSUUN3ME2zOU42PTl6IN88US=>	NUi3elFHW0GQR1XS
NCI-H1395	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXqRZYyUUN3ME2zOU43PjlzIN88US=>	MYTTRW5ITVJ?
J-RT3-T3-5	MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rzUGlEPTB;M{[uNFI6PCEQvF2=	Ml7iV2FPT0WU
COR-L279	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTN4LkG5PFEh\|ryP	MVLTRW5ITVJ?
ATN-1	NGjiOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrSc4ZKSzVyPUO2Mlg2OTZizszN	NIHvTYdUSU6JRWK=
HCC2998	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjj[2hKSzVyPUO2Mlg2PzFizszN	MVrTRW5ITVJ?
UM-UC-3	NEHMT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\GfGlEPTB;M{[uPFY4PSEQvF2=	MXnTRW5ITVJ?
DV-90	NYLXWWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2P0cmlEPTB;M{[uPVA3PyEQvF2=	MlzZV2FPT0WU
ES8	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXu3cnFoUUN3ME2zOk46OzF6IN88US=>	NX;JSY91W0GQR1XS
YAPC	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoqzTWM2OD1\|Nj65OlU1KM7:TR?=	NW\FfJp3W0GQR1XS
HCC1599	NXPLVIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfkdZB4UUN3ME2zO{4yPjF6IN88US=>	NWfMXJE5W0GQR1XS
UMC-11	NHXZdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7qWWJKSzVyPUO3MlI2ODNizszN	M{C4fHNCVkeHUh?=
THP-1	NXzsVZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXweVhKSzVyPUO3MlI5PjhizszN	MWDTRW5ITVJ?
OCUB-M	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XyOGlEPTB;M{euNlg6OSEQvF2=	M4GxPXNCVkeHUh?=
NCI-H1693	NInFVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\lTWM2OD1\|Nz6zNlM{KM7:TR?=	NH;0NGhUSU6JRWK=
NCI-H345	M1foRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXK0cFREUUN3ME2zO{4{PjJ2IN88US=>	NH35TllUSU6JRWK=
COLO-800	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVH3VItOUUN3ME2zO{42PjdizszN	MknLV2FPT0WU
COLO-320-HSR	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvMTWM2OD1\|OD6zOFkzKM7:TR?=	NWXsZ4hoW0GQR1XS
NCI-H596	Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHn0[mhKSzVyPUO4MlQ1QDlizszN	MmHQV2FPT0WU
NCI-H187	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{n0fGlEPTB;M{iuO\|M1PCEQvF2=	NYm5c2tsW0GQR1XS
ECC4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:2cWxoUUN3ME2zPU4xQDF2IN88US=>	NIfSRZpUSU6JRWK=
KP-4	NUDUd5EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfGTWM2OD1\|OT6xNlM2KM7:TR?=	NH7TWolUSU6JRWK=
NCI-H2227	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDUR2w6UUN3ME2zPU4{QTR7IN88US=>	M2ezdXNCVkeHUh?=
22RV1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXn5boYyUUN3ME2zPU45Ozl6IN88US=>	M1fYRnNCVkeHUh?=
SAS	NHPkRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXafXIyUUN3ME20NE4xQTZizszN	M2nnZnNCVkeHUh?=
PANC-10-05	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT5TWM2OD12MD6xPFI5KM7:TR?=	NH;LW2NUSU6JRWK=
MDA-MB-468	NI\odZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\jcGlEPTB;NECuOVM1PiEQvF2=	NGrVcZJUSU6JRWK=
RPMI-7951	NUTRUYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rlOWlEPTB;NEGuNlA4PSEQvF2=	MkDxV2FPT0WU
BB49-HNC	NIPTfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLyTWM2OD12MT6yNVc6KM7:TR?=	NIm5TolUSU6JRWK=
23132-87	NW\aSWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TKbWlEPTB;NEGuNlc{OiEQvF2=	M3HoNHNCVkeHUh?=
HCC1569	NXu4PXFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTRzLkK4PFUh\|ryP	M1flfHNCVkeHUh?=
CP66-MEL	NVv6flhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPwSGdKSzVyPUSyMlE5QDZizszN	MVzTRW5ITVJ?
K-562	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVX4RZBvUUN3ME20Nk4zQDV2IN88US=>	NG\kV\|ZUSU6JRWK=
OCI-AML2	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTWcmRUUUN3ME20Nk45QTd2IN88US=>	MXPTRW5ITVJ?
SW756	NYeyWpo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTMOoE1UUN3ME20N{4xOzh6IN88US=>	MUDTRW5ITVJ?
M14	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHOTWM2OD12Mz6zNVg6KM7:TR?=	NVTqdVZ[W0GQR1XS
NCI-H1623	NIHN[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;STWM2OD12Mz60OlQh\|ryP	MUjTRW5ITVJ?
KNS-81-FD	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrZTG5IUUN3ME20N{44PjJizszN	M4PnV3NCVkeHUh?=
TGBC1TKB	M{Lje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[xWW5UUUN3ME20N{46ODl7IN88US=>	M2jle3NCVkeHUh?=
RERF-LC-MS	NFXUfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LEdmlEPTB;NEOuPVI5OSEQvF2=	M2iySnNCVkeHUh?=
PC-3	NFvPXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIT5NHdKSzVyPUS0MlQ{PDdizszN	NGPCc3ZUSU6JRWK=
HuP-T4	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDaTVA4UUN3ME20OE41PDd2IN88US=>	M3vyS3NCVkeHUh?=
NCI-H510A	NFrwVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn2TWM2OD12ND63NFgh\|ryP	NXHOe3VWW0GQR1XS
LB2518-MEL	NFjRZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTR2Lke5N\|ch\|ryP	NEnsNodUSU6JRWK=
TE-5	NHrOdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFH1UmJKSzVyPUS1Mlk2QDFizszN	Mn7mV2FPT0WU
EW-24	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXDTWM2OD12Nj6xO\|I{KM7:TR?=	MX3TRW5ITVJ?
LB647-SCLC	NEXIdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTR4LkKxOVUh\|ryP	NVLFNpJ5W0GQR1XS
NCI-H524	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHzfWdCUUN3ME20Ok44OTh3IN88US=>	NX\BNXE5W0GQR1XS
EW-11	M{Da[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13uPGlEPTB;NE[uPVM4OyEQvF2=	Mlf0V2FPT0WU
KALS-1	NHqzZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37ISmlEPTB;NEeuNlA3PiEQvF2=	NHTvVZhUSU6JRWK=
BT-474	M4fMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV22dJRQUUN3ME20O{41OjF4IN88US=>	M3PoTHNCVkeHUh?=
SK-N-AS	NWL6SmRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j6NWlEPTB;NEeuPFg5KM7:TR?=	M3jkWnNCVkeHUh?=
HCC2157	M3voNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVqweJd6UUN3ME20PE4xPzZizszN	MXXTRW5ITVJ?
HCC1954	NEDRSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTR6LkG3NFQh\|ryP	M2njUnNCVkeHUh?=
FADU	NYr4WWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTR6LkOwN\|Eh\|ryP	MWTTRW5ITVJ?
S-117	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzUe214UUN3ME20PE4{QDF3IN88US=>	M2rXSHNCVkeHUh?=
LS-1034	M3ThTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfxZ5BvUUN3ME20PE44ODZ5IN88US=>	MmCwV2FPT0WU
CAMA-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrEVJVOUUN3ME20PU42PTR\|IN88US=>	NXnWdZRGW0GQR1XS
LU-134-A	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3exeWlEPTB;NEmuPFA5PSEQvF2=	NILZS2VUSU6JRWK=
NCI-H1838	NFXyO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PLNWlEPTB;NEmuPFA5PyEQvF2=	MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	- Collapse Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Formulation: Dissolved in 25 mM citrate buffer, pH 2.75 Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CN1CCN(CC1)CC2=C(C=C(NC(=O)C3=CC(=C(C)C=C3)C#CC4=CN=C5C=CC=N[N]45)C=C2)C(F)(F)F

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04070443	Not yet recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	October 1 2019	Phase 2
NCT03934372	Not yet recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	October 25 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)